NMRK vs SBRA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NMRK presents a compelling value opportunity characterized by a stable Piotroski F-Score of 4/9 and a significant disconnect between its current price ($15.73) and its growth-based intrinsic value ($20.06). While the Graham Number suggests a more conservative floor of $11.09, the Forward P/E of 7.43 indicates the market is severely underpricing expected earnings growth. Explosive YoY earnings growth of 146.9% and a consistent track record of beating estimates provide a strong fundamental tailwind, though tight short-term liquidity remains a concern.
SBRA presents a precarious financial profile with a Piotroski F-Score of 4/9, indicating only stable, non-strong health. The stock is trading at a severe premium to both its Graham Number ($12.71) and Intrinsic Value ($4.48), while maintaining a dangerous dividend payout ratio of 187.5%. Despite double-digit revenue growth, the company is experiencing a sharp contraction in earnings (-44.7% YoY), suggesting a fundamental disconnect between top-line growth and profitability. The combination of bearish technicals, negative insider sentiment, and unsustainable dividends suggests a value trap despite optimistic analyst targets.
Compare Another Pair
Related Comparisons
NMRK vs SBRA: Head-to-Head Comparison
This page compares Newmark Group, Inc. (NMRK) and Sabra Health Care REIT, Inc. (SBRA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.